PTEN and glioblastoma: Loss of PTEN function through deletion, mutation or down regulation has been found to potentially enrich sensitivity to small molecule inhibitors of PI3Kβ such as AZD8186 and GSK2636771, as studied in cell line panels and early clinical trials of patients with PTEN-deficient advanced solid tumors including GBM, respectively32,33.